75 patents
Page 4 of 4
Utility
Methods of Preparing Cytotoxic Benzodiazepine Derivatives
3 Jun 20
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Michael Reardon, Richard A. Silva
Filed: 10 Nov 19
Utility
Selective Sulfonation of Benzodiazepine Derivatives
20 May 20
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group.
Scott A. Hilderbrand, Benjamin M. Hutchins
Filed: 29 Oct 19
Utility
Methods of Treatment Using ANTI-CD123 Immunoconjugates
20 May 20
Methods of administering immunoconjugates that bind to CD123 are provided.
Patrick ZWEIDLER-MCKAY, Kerry CULM-MERDEK, Callum SLOSS, Angela ROMANELLI
Filed: 29 Oct 19
Utility
Cross-linkers and Their Uses
13 May 20
Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
Filed: 13 Oct 19
Utility
Methods for the Acylation of Maytansinol
13 May 20
Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent.
Wayne C. Widdison, Robert Yongxin Zhao
Filed: 17 Sep 19
Utility
Methods of Preparing Indolinobenzodiazepine Derivatives
8 Apr 20
Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
Filed: 3 Sep 19
Utility
Process for Preparing Cell-binding Agent-cytotoxic Agent Conjugates
1 Apr 20
Benjamin M. Hutchins
Filed: 6 Aug 19
Utility
Anti-FOLR1 Immunoconjugate Dosing Regimens
12 Feb 20
Methods of administering immunoconjugates that bind to FOLR1 are provided.
Kelli RUNNING, Robert A. MASTICO, James J. O'LEARY, Olga AB, Beni WOLF
Filed: 18 Apr 19
Utility
Methods of Treatment Using Anti-erbb Antibody-maytansinoid Conjugates
12 Feb 20
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods.
Walter Blattler, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
Filed: 18 Feb 19
Utility
Methods of Preparing Cytotoxic Benzodiazepine Derivatives
15 Jan 20
The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
Filed: 20 Jun 19
Utility
Methods of Preparing Cytotoxic Benzodiazepine Derivatives
1 Jan 20
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
Filed: 16 Jun 19
Utility
Methods of Preparing Cytotoxic Benzodiazepine Derivatives
25 Dec 19
The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
Filed: 5 Jun 19
Utility
Methods for Formulating Antibody Drug Conjugate Compositions
4 Dec 19
The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
Gillian Payne, Robert W. Herbst, Juma Bridgewater
Filed: 8 May 19
Utility
Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
13 Nov 19
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided.
Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
Filed: 14 Apr 19
Utility
Selective Sulfonation of Benzodiazepine Derivatives
16 Oct 19
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group.
Scott A. Hilderbrand, Benjamin M. Hutchins
Filed: 25 Mar 19